Observational studyJournal of translational medicine2026
Superior 12-month progression-free survival with frontline DVd versus VRd in patients with newly diagnosed multiple myeloma: a multicenter propensity score-matched analysis.
Huinan Jiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.